Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) does about 13.88M shares in volume on a normal day but saw 6207031 shares change hands in Friday trading. The company now has a market cap of 50.41M USD and an enterprise value of about $50.67M. Its current market price is $0.29, marking an increase of 4.73% compared to the previous close of $0.28. The 52 week high reached by this stock is $1.13 whilst the lowest price level in 52 weeks is $0.20. The script in recent trading has seen the stock touch a high of $0.295 and a low of $0.2792.

Sunesis Pharmaceuticals Inc. (SNSS) has a 20-day trading average at $0.2946 and the current price is -74.12% off the 52-week high compared with 49.92% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.3135 and its 200-day simple moving average is $0.4513. If we look at the stock’s price movements over the week, volatility stands at 6.51%, which increases to 9.37% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 48.08 to suggest the stock is neutral.

3 analysts observing the Sunesis Pharmaceuticals Inc. (SNSS) stock have set the 12-month price targets for the company’s shares at between $1.00 and $1.00. The median price target is 71.0% away from the current levels at $1.00.

FactSet Research has provided data showing that 3 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 2 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Hold the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 24, 2020 when Oppenheimer downgraded the stock to “Perform” and issued a price target of. Wells Fargo also downgraded the stock to “Equal Weight” from Overweight on March 11, 2020 at a price target of $3-$1.

The current price level is -0.91%, -8.35%, and -35.31% away from its SMA20, SMA50, and SMA200 respectively, with the SNSS price moving above the 50-day SMA on August 28. Sunesis Pharmaceuticals Inc. (SNSS) stock is up 1.21% over the week and 3.25% over the past month. Its price is -13.38% year-to-date and -64.16% over the past year.

The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.06 below consensus estimates by $0. The company’s next earnings report is expected on 11/04/2020, with forecasts estimating quarterly EPS at -$0.03 and -$0.16 for whole year. SNSS’s earnings per share are forecast to grow by 40.70% this year and 18.80% over next year.

Its 12-month price target is $1.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $1.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $1.00.

Outstanding shares total 111.42M with insiders holding 0.18% of the shares and institutional holders owning 62.41% of the company’s common stock. The company has a return on investment of -109.80% and return on equity of -183.60%. The beta has a value of 1.76. Price to book ratio is 7.31 and price to sales ratio is 22.91.

According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has reduced its position in Sunesis Pharmaceuticals Inc. (SNSS) to 2,860,014 shares, mirroring a recent drop by 0.00%. Vanguard Total Stock Market Index dumped 0.0 shares of Sunesis Pharmaceuticals Inc. common stock bringing its total worth to about $0.87 million at the end of recent close, SEC documents show. Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by Vanguard Extended Market Index Fu, which sold off 0.0 shares to end up with 1,263,683 shares worth $0.38 million. Fidelity Extended Market Index Fu cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 0.26% position in Sunesis Pharmaceuticals Inc. thanks to 0.42 million shares amounting to $0.13 million.